Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed classical Hodgkin's lymphoma Relapsed disease with achievement of at least a partial response or a metabolic response to most recent salvage therapy No primary induction failure, defined as disease progression during or within 2 months after completion of first-line therapy PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL* NOTE: *Unless due to lymphoma or Gilbert's syndrome Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ 45% by echocardiogram or MUGA Pulmonary DLCO ≥ 50% of predicted (corrected for alveolar volume) Immunologic No known HIV positivity No active infection requiring oral or IV antibiotics No autoimmune or other disease requiring long-term systemic steroids or other long-term immunosuppressants Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Able to tolerate high-dose therapy No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior bone marrow transplantation Endocrine therapy Not specified Radiotherapy Concurrent radiotherapy for disease progression after high-dose cyclophosphamide allowed at the discretion of the principal investigator Surgery Not specified